Hepatitis B News and Research RSS Feed - Hepatitis B News and Research

Hepatitis B is one type of hepatitis – a liver disease- caused by the hepatitis B virus (HBV). Hepatitis B spreads by contact with an infected person's blood, semen or other body fluid. An infected woman can give hepatitis B to her baby at birth.

If you get HBV, you may feel as if you have the flu, or you may have no symptoms at all. A blood test can tell if you have it. HBV usually gets better on its own after a few months. If it does not get better, it is called chronic HBV, which lasts a lifetime. Chronic HBV can lead to scarring of the liver, liver failure or liver cancer.

There is a vaccine for HBV. It requires three shots. All babies should get the vaccine, but older children and adults can get it too. If you travel to countries where Hepatitis B is common, you should get the vaccine.
T-bet protein fights off hepatitis infections

T-bet protein fights off hepatitis infections

A single protein may tip the balance between ridding the body of a dangerous virus and enduring life-long chronic infection, according to a report appearing in The Journal of Experimental Medicine. [More]
AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie today announced results from a Phase 3 pivotal study demonstrating that HUMIRA® (adalimumab) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and inflammatory nodules. [More]
Novira completes Phase 1a clinical study of NVR-1221 for treatment of HBV infection

Novira completes Phase 1a clinical study of NVR-1221 for treatment of HBV infection

Novira Therapeutics, Inc., a privately held biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection, today announced successful completion of a Phase 1a clinical study of NVR-1221. [More]
High uptake of US infant vaccination in 2013

High uptake of US infant vaccination in 2013

The recently published National Immunization Survey (NIS) conducted by the CDC, shows that the majority of infants in the US were vaccinated against potentially serious diseases in 2013. Fewer than 1% of children were unvaccinated in 2013. [More]
FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

ViiV Healthcare announced today that the US Food and Drug Administration has approved Triumeq (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection. [More]
ITS develops new T cell vaccine to protect humans from seasonal and pandemic influenza A

ITS develops new T cell vaccine to protect humans from seasonal and pandemic influenza A

Immune Targeting Systems, specializing in the development of novel T cell immune therapies, has been developing an exciting new T cell vaccine (FlunisynTM) designed to protect humans from all strains of seasonal and pandemic influenza A. [More]
Oncolytics Biotech announces financial results and operational highlights for second quarter 2014

Oncolytics Biotech announces financial results and operational highlights for second quarter 2014

Oncolytics Biotech Inc. today announced its financial results and operational highlights for the second quarter ended June 30, 2014. [More]
New technique for studying lifecycle of hepatitis B virus can help develop cure for disease

New technique for studying lifecycle of hepatitis B virus can help develop cure for disease

A new technique for studying the lifecycle of the hepatitis B virus could help researchers develop a cure for the disease. [More]
Trials show immunizations are effective in adults

Trials show immunizations are effective in adults

As kids prepare to head back to school, required immunizations are typically on the to-do list, but getting potentially lifesaving vaccines should not end when adulthood begins, says one University of Alabama at Birmingham infectious diseases expert. [More]
New momentum: WHO welcomes progress in tackling viral hepatitis

New momentum: WHO welcomes progress in tackling viral hepatitis

On World Hepatitis Day, 28 July, WHO welcomes new progress in tackling one of the world's most serious diseases. Viral hepatitis - a group of infectious diseases known as hepatitis A, B, C, D, and E - affects millions of people worldwide, causing acute and chronic liver disease and killing close to 1.4 million people every year. [More]
Isis earns $1 million payment from GSK related to advancement of ISIS-TTRRx

Isis earns $1 million payment from GSK related to advancement of ISIS-TTRRx

Isis Pharmaceuticals, Inc. announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP). [More]

CRAG urges researchers to balance goal of shortening treatment for MDR-TB with patient safety

In a viewpoint published this week in The Lancet, the Community Research Advisors Group argue that research into bedaquiline – a new drug, fast tracked for multidrug-resistant tuberculosis (MDR-TB) – should proceed cautiously in people with drug-sensitive tuberculosis. [More]
UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology. [More]
New meta-analysis highlights significant gaps in hepatitis C care

New meta-analysis highlights significant gaps in hepatitis C care

A new meta-analysis published online in PLOS ONE by infectious disease and epidemiology specialists from the Perelman School of Medicine at the University of Pennsylvania highlights significant gaps in hepatitis C care that will prove useful as the U.S. health care system continues to see an influx of patients with the disease because of improved screening efforts and new, promising drugs. [More]
Isis Pharmaceuticals gets $1 million from GSK to discover and develop drugs for HBV

Isis Pharmaceuticals gets $1 million from GSK to discover and develop drugs for HBV

Isis Pharmaceuticals, Inc. announced today that it has earned a $1 million payment from GlaxoSmithKline related to the advancement of its program to develop antisense drugs to treat hepatitis B virus (HBV). [More]
Biotest Pharmaceuticals opens new plasma collection center in Valdosta, Georgia

Biotest Pharmaceuticals opens new plasma collection center in Valdosta, Georgia

Biotest Pharmaceuticals Corporation, a leading developer of immunology biotherapeutic products, is pleased to announce the addition of its newest plasma collection center located at 311 North Patterson Road, in Valdosta, Georgia. [More]
Alcoholic liver disease: an interview with Dr Vinood Patel, University of Westminster

Alcoholic liver disease: an interview with Dr Vinood Patel, University of Westminster

Alcoholic liver disease (ALD) is one of the leading causes of death worldwide and also in the UK. As its name indicates this disease arises due to consuming excessive amounts of alcohol (80 g/day) over an extended period, normally 10-20 years. [More]
Antiviral therapy can reduce risk of liver cancer in patients with chronic hepatitis B infection

Antiviral therapy can reduce risk of liver cancer in patients with chronic hepatitis B infection

One of the most severe complications of hepatitis B is the development of liver cancer, which is responsible for approximately 745,000 deaths worldwide each year. [More]
Arrowhead Research joins with broad-market Russell 3000 Index

Arrowhead Research joins with broad-market Russell 3000 Index

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, is set to join the broad-market Russell 3000 Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, according to a preliminary list of additions posted June 13 on www.russell.com/indexes. [More]
Janssen, Viiv Healthcare to develop single tablet regimen for maintenance treatment of HIV

Janssen, Viiv Healthcare to develop single tablet regimen for maintenance treatment of HIV

Janssen R&D Ireland Ltd announced today that they have entered into a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (marketed as EDURANT®) and ViiV's Integrase Inhibitor dolutegravir(marketed as TIVICAY®) as the sole active ingredients for the maintenance treatment of people living with Human Immunodeficiency Virus (HIV). [More]